| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.71B | 5.58 | 57.41 | 43.5% | 9.32% | 1.92% | ||
| CORTCorcept Therapeutics Incorporated | 3.72B | 35.39 | 28.77 | 39.94% | 14.19% | 16.65% | 5.26% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 302.14M | 1.97 | -1.22 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 465.15M | 1.28 | -2.03 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 260.56M | 2.81 | -2.87 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 172.89M | 2.03 | -3.03 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 442.41M | 4.24 | -3.16 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 771.24M | 21.51 | -3.24 | -12.81% | -27.32% | 0.03 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales/Revenue | 0 | 0 |
| Revenue Growth % | - | - |
| Cost of Goods Sold | 0 | 0 |
| COGS % of Revenue | - | - |
| Gross Profit | 0 | 0 |
| Gross Margin % | - | - |
| Gross Profit Growth % | - | - |
| Operating Expenses | 43.67M | 224.83M |
| OpEx % of Revenue | - | - |
| Selling, General & Admin | 15.04M | 26.8M |
| SG&A % of Revenue | - | - |
| Research & Development | 15.56M | 107.52M |
| R&D % of Revenue | - | - |
| Other Operating Expenses | 13.06M | 90.52M |
| Operating Income | -43.67M | -224.83M |
| Operating Margin % | - | - |
| Operating Income Growth % | - | -4.15% |
| EBITDA | -43.67M | -224.82M |
| EBITDA Margin % | - | - |
| EBITDA Growth % | - | -4.15% |
| D&A (Non-Cash Add-back) | 2K | 14K |
| EBIT | -47.21M | -218.24M |
| Net Interest Income | 1.92M | 5.96M |
| Interest Income | 1.92M | 6.18M |
| Interest Expense | 0 | 223K |
| Other Income/Expense | -3.54M | 6.37M |
| Pretax Income | -47.21M | -218.47M |
| Pretax Margin % | - | - |
| Income Tax | 0 | -9.34M |
| Effective Tax Rate % | 1% | 0.96% |
| Net Income | -47.21M | -209.13M |
| Net Margin % | - | - |
| Net Income Growth % | - | -3.43% |
| Net Income (Continuing) | -47.21M | -209.13M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | -0.95 | -2.03 |
| EPS Growth % | - | -1.14% |
| EPS (Basic) | -0.95 | -2.03 |
| Diluted Shares Outstanding | 49.94M | 103.04M |
| Basic Shares Outstanding | 49.94M | 103.04M |
| Dividend Payout Ratio | - | - |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Total Current Assets | 76.8M | 359.13M |
| Cash & Short-Term Investments | 75.19M | 352.45M |
| Cash Only | 75.19M | 352.45M |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 0 | 0 |
| Days Sales Outstanding | - | - |
| Inventory | 0 | 0 |
| Days Inventory Outstanding | - | - |
| Other Current Assets | 761K | 4.63M |
| Total Non-Current Assets | 92.04M | 91.86M |
| Property, Plant & Equipment | 27K | 1.44M |
| Fixed Asset Turnover | - | - |
| Goodwill | 22.18M | 21.89M |
| Intangible Assets | 69.42M | 68.52M |
| Long-Term Investments | 0 | 0 |
| Other Non-Current Assets | 410K | 0 |
| Total Assets | 168.84M | 450.99M |
| Asset Turnover | - | - |
| Asset Growth % | - | 1.67% |
| Total Current Liabilities | 20.17M | 67.31M |
| Accounts Payable | 2.66M | 20.84M |
| Days Payables Outstanding | - | - |
| Short-Term Debt | 0 | 8.39M |
| Deferred Revenue (Current) | 0 | 0 |
| Other Current Liabilities | 14.86M | 25.32M |
| Current Ratio | 3.81x | 5.34x |
| Quick Ratio | 3.81x | 5.34x |
| Cash Conversion Cycle | - | - |
| Total Non-Current Liabilities | 50.17M | 96.33M |
| Long-Term Debt | 0 | 0 |
| Capital Lease Obligations | 0 | 701K |
| Deferred Tax Liabilities | 17.67M | 7.78M |
| Other Non-Current Liabilities | 32.5M | 87.85M |
| Total Liabilities | 70.34M | 163.64M |
| Total Debt | 0 | 9.8M |
| Net Debt | -75.19M | -342.64M |
| Debt / Equity | - | 0.03x |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | - | -1008.22x |
| Total Equity | 98.5M | 287.35M |
| Equity Growth % | - | 1.92% |
| Book Value per Share | 1.97 | 2.79 |
| Total Shareholders' Equity | 98.5M | 287.35M |
| Common Stock | 0 | 0 |
| Retained Earnings | -48.02M | -257.15M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 2.75M | 1.16M |
| Minority Interest | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | -35.39M | -99.79M |
| Operating CF Margin % | - | - |
| Operating CF Growth % | - | -1.82% |
| Net Income | -47.21M | -209.13M |
| Depreciation & Amortization | 2K | 14K |
| Stock-Based Compensation | 85K | 0 |
| Deferred Taxes | 0 | -9.34M |
| Other Non-Cash Items | 7.7M | 92.92M |
| Working Capital Changes | 4.02M | 25.75M |
| Change in Receivables | 0 | 0 |
| Change in Inventory | 0 | 0 |
| Change in Payables | 2.6M | 16.55M |
| Cash from Investing | -28.24M | -43K |
| Capital Expenditures | -29K | -43K |
| CapEx % of Revenue | - | - |
| Acquisitions | - | - |
| Investments | - | - |
| Other Investing | 0 | 0 |
| Cash from Financing | 123.68M | 377.95M |
| Debt Issued (Net) | - | - |
| Equity Issued (Net) | - | - |
| Dividends Paid | 0 | 0 |
| Share Repurchases | - | - |
| Other Financing | -217K | -18.98M |
| Net Change in Cash | - | - |
| Free Cash Flow | -35.42M | -99.83M |
| FCF Margin % | - | - |
| FCF Growth % | - | -1.82% |
| FCF per Share | -0.71 | -0.97 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.48x |
| Interest Paid | 0 | 0 |
| Taxes Paid | 0 | 0 |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Equity (ROE) | -47.92% | -108.4% |
| Debt / Equity | - | 0.03x |
| Interest Coverage | - | -1008.22x |
| FCF Conversion | 0.75x | 0.48x |
Metsera, Inc. (MTSR) grew revenue by 0.0% over the past year. Growth has been modest.
Metsera, Inc. (MTSR) reported a net loss of $314.4M for fiscal year 2024.
Metsera, Inc. (MTSR) has a return on equity (ROE) of -108.4%. Negative ROE indicates the company is unprofitable.
Metsera, Inc. (MTSR) had negative free cash flow of $231.6M in fiscal year 2024, likely due to heavy capital investments.